A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)

NCT05543174 | Completed Phase 3 Results FDA Drug

• 2 other identifiers: TAK-625-3001jRCT2051220098
• Study Type: interventional
• Target: 7
• Locations: 1 country
• Sites: 8

Brief Summary

The main aim of the study is to check if TAK-625 improves symptoms of Alagille Syndrome (ALGS), side effect from the study treatment or TAK-625, and how much TAK-625 stays in their blood over time. This will help the study sponsor (Takeda) to work out the best dose to give people in the future. The participants will be treated with TAK-625 for up to the end of study (about 34 months). Participants will visit their study clinic 9 times from the start of study. After 9 times visits, participants will visit their study clinic every 12 weeks up to the end of study.

Conditions

Alagille Syndrome (ALGS)

Outcome Measures

Primary Outcomes (1)

• Change in Fasting Serum Bile Acid (sBA) Levels From Week 18 to Week 22

  Change in fasting sBA levels from Week 18 to 22 was reported. Change was calculated as: observed value at Week 22- observed value at Week 18.

  From Week 18 to Week 22

Secondary Outcomes (13)

• Change in Fasting sBA Levels From Baseline to Week 18

  Baseline to Week 18

• Change in Weekly Average Severity of Pruritus Measured by Itch Reported Outcome (ItchRO) (Observer Instrument [Obs]) From Baseline to Week 18

  Baseline to Week 18

• Change in Weekly Average Morning Severity of Pruritus Measured by Itch Reported Outcome (ItchRO) (Observer Instrument [Obs]) From Baseline to Week 18

  Baseline to Week 18

• Change in Weekly Average Severity of Pruritus Measured by ItchRO (Obs) From Week 18 to Week 22

  From Week 18 to Week 22

• Change in Weekly Average Morning Severity of Pruritus Measured by ItchRO (Obs) From Week 18 to Week 22

  From Week 18 to Week 22

Study Arms (1)

TAK-625

EXPERIMENTAL

TAK-625 200 mcg per kilogram, orally, once daily for 1 week. After that, TAK-625 400 mcg per kilogram, orally, once daily after Week 1.

Drug: TAK-625

Interventions

TAK-625 DRUG

TAK-625 200 mcg or 400 mcg per kilogram, orally, once daily

Also known as: Maralixibat chloride

TAK-625

Eligibility Criteria

• Age: 1 Month+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• The participant is Japanese male or female with a body weight \>=3.0 kilograms (kg) and who is \>=1 month of age at the time of informed consent.
• The participant is diagnosed with ALGS.
• The participant has one or more of the following evidences of cholestasis:
• Total serum bile acid (sBA) \>3\^ upper limit of the normal range (ULN) for age.
• Direct bilirubin (conjugated) \>1 mg/dL.
• Lipid soluble vitamin (LSV) deficiency otherwise unexplainable.
• Gamma-glutamyl transferase (GGT) \>3\^ ULN for age.
• Intractable pruritus explainable only by liver disease.
• The participant is expected to have a consistent caregiver(s) for the duration of the study.
• The participant has an access to phone for scheduled calls from study site.
• Both a caregiver and participant above the age of assent are capable of reading and understanding the questionnaires.
• Caregivers (and age-appropriate participants) must be willing and able to use an eDiary device during the study.
• Caregivers (and age-appropriate participants) must complete at least 10 eDiary reports (morning or evening) during each of 2 consecutive weeks of the screening period (maximum possible reports=14 per week), even if the participant is an adult (over 18 years old).
• Average daily score \>2 on the ItchRO questionnaire (maximum possible daily score of 4) for 2 consecutive weeks in the screening period, prior to dosing. A daily score is the higher of the scores for the morning and evening ItchRO. The average daily score is the sum of all daily scores divided by the number of days the ItchRO was completed. Since it is difficult to evaluate pruritus in infants, participants \<12 months of age at screening whose pruritus is unavoidably difficult to be evaluated are not necessarily required to meet the above score.

You may not qualify if:

• The participant has chronic diarrhea requiring ongoing intravenous (IV) fluid or nutritional intervention.
• The participant has a previous history of surgical interruption of the enterohepatic circulation.
• The participant has a previous liver transplant.
• The participant decompensated cirrhosis (ALT \>15\^ ULN, international normalized ratio \[INR\] \>1.5 \[unresponsive to vitamin K therapy\], albumin \<3.0 g/dL, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy).
• The participant has a history or presence of other concomitant liver disease.
• The participant has a history or presence of any other disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs, including bile salt metabolism in the intestine (eg, inflammatory bowel disease).
• The participant has a history or presence of gallstones or kidney stones.
• The participant has a possible malignant liver mass in imaging, including screening ultrasound.
• The participant has cancers, except for in situ carcinoma, or cancers treated at least 5 years prior to screening with no evidence of recurrence.
• The participant has received bile acid/lipid binding resins or IBAT inhibitors within 28 days prior to screening and throughout the trial.
• The participant who has received sodium phenylbutyrate for less than 6 months at the initiation of screening.

Sponsors & Collaborators

• Takeda: lead

Study Sites (8)

University of Tsukuba Hospital

Tsukuba, Ibaraki, Japan

Location

Yokohamashi Tobu Hospital

Yokohama, Kanagawa, Japan

Location

Miyagi Children's Hospital

Sendai, Miyagi, Japan

Location

Kindai University Nara Hospital

Ikoma, Nara, Japan

Location

Osaka University Hospital

Suita, Osaka, Japan

Location

Juntendo University Hospital

Bunkyo-ku, Tokyo, Japan

Location

Kyoto University Hospital

Kyoto, Japan

Location

Saitama Prefectural Children's Medical Center

Saitama, Japan

Location

Related Links

• To obtain more information on the study, click here/on this link

MeSH Terms

Conditions

Alagille Syndrome

Condition Hierarchy (Ancestors)

Cholestasis, Intrahepatic; Cholestasis; Bile Duct Diseases; Biliary Tract Diseases; Digestive System Diseases; Liver Diseases; Heart Defects, Congenital; Cardiovascular Abnormalities; Cardiovascular Diseases; Abnormalities, Multiple; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Genetic Diseases, Inborn

Results Point of Contact

• Title: Study Director
• Organization: Takeda

TrialDisclosures@takeda.com

+1-877-825-3327

Study Officials

• Study Director

  Takeda

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 14, 2022
• First Posted: September 16, 2022
• Study Start: January 16, 2023
• Primary Completion: October 25, 2023
• Study Completion: July 25, 2025
• Last Updated: January 29, 2026
• Results First Posted: October 15, 2024

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

JP (8)